Do analysts rate PLUR or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PLUR or MBIO more profitable?

Mustang Bio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Mustang Bio N/A -34.23% -17.55%

Do analysts recommend MBIO or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MBIO or OSRH more profitable?

Mustang Bio has a net margin of 0.00% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% OSR -363.26% -7.24% -5.41%

Do analysts prefer MBIO or APLT?

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is MBIO or APLT more profitable?

Mustang Bio's return on equity of -34.23% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Applied Therapeutics N/A -340.84% -175.00%

Do analysts prefer HIND or MBIO?

Vyome currently has a consensus target price of $15.00, indicating a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher probable upside, equities analysts plainly believe Vyome is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HIND or MBIO more profitable?

Mustang Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Mustang Bio's return on equity of -34.23% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Mustang Bio N/A -34.23% -17.55%

Do analysts prefer MBIO or PASG?

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 188.67%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has preferable valuation & earnings, MBIO or PASG?

Mustang Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.45 N/A Passage Bio N/A N/A -$45.52M -$11.32 N/A

Is MBIO or PASG more profitable?

Mustang Bio's return on equity of -34.23% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -34.23% -17.55% Passage Bio N/A -218.59% -72.93%

Mustang Bio (MBIO) Competitors

$0.59 0.00 (-0.08%)

As of 03:56 PM Eastern

Compare

MBIO vs. PLUR, OSRH, APLT, HIND, and PASG

Should you buy Mustang Bio stock or one of its competitors? Mustang Bio's main competitors and comparable companies include Pluri (PLUR), OSR (OSRH), Applied Therapeutics (APLT), Vyome (HIND), and Passage Bio (PASG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mustang Bio compare to Pluri?

Pluri (NASDAQ:PLUR) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Mustang Bio has lower revenue, but higher earnings than Pluri. Mustang Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

Mustang Bio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Mustang Bio	N/A	-34.23%	-17.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.6% of Pluri shares are held by institutional investors. Comparatively, 9.9% of Mustang Bio shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 4.0% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 1.89 beat Mustang Bio's score of 1.87 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
Mustang Bio	Very Positive

Pluri has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market.

Summary

Pluri beats Mustang Bio on 6 of the 11 factors compared between the two stocks.

How does Mustang Bio compare to OSR?

Mustang Bio (NASDAQ:MBIO) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

9.9% of Mustang Bio shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by insiders. Comparatively, 36.9% of OSR shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, OSR had 5 more articles in the media than Mustang Bio. MarketBeat recorded 6 mentions for OSR and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.87 beat OSR's score of 0.49 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Very Positive
OSR	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mustang Bio has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Comparatively, OSR has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Mustang Bio has higher earnings, but lower revenue than OSR. Mustang Bio is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
OSR	$2.91M	3.81	-$27.06M	-$0.33	N/A

Mustang Bio has a net margin of 0.00% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
OSR	-363.26%	-7.24%	-5.41%

Summary

OSR beats Mustang Bio on 8 of the 12 factors compared between the two stocks.

How does Mustang Bio compare to Applied Therapeutics?

Mustang Bio (NASDAQ:MBIO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Mustang Bio has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

Mustang Bio has higher earnings, but lower revenue than Applied Therapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

In the previous week, Mustang Bio had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Mustang Bio and 0 mentions for Applied Therapeutics. Mustang Bio's average media sentiment score of 1.87 beat Applied Therapeutics' score of 0.00 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Very Positive
Applied Therapeutics	Neutral

9.9% of Mustang Bio shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mustang Bio's return on equity of -34.23% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Applied Therapeutics	N/A	-340.84%	-175.00%

Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Applied Therapeutics beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Vyome?

Vyome (NASDAQ:HIND) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Vyome has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.06, meaning that its stock price is 106% more volatile than the broader market.

22.1% of Vyome shares are held by institutional investors. Comparatively, 9.9% of Mustang Bio shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 4.0% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mustang Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Mustang Bio's return on equity of -34.23% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Mustang Bio	N/A	-34.23%	-17.55%

Mustang Bio has lower revenue, but higher earnings than Vyome. Mustang Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

In the previous week, Vyome had 1 more articles in the media than Mustang Bio. MarketBeat recorded 2 mentions for Vyome and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.87 beat Vyome's score of 1.47 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Vyome	Positive
Mustang Bio	Very Positive

Vyome currently has a consensus target price of $15.00, indicating a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher probable upside, equities analysts plainly believe Vyome is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vyome beats Mustang Bio on 8 of the 15 factors compared between the two stocks.

How does Mustang Bio compare to Passage Bio?

Mustang Bio (NASDAQ:MBIO) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Mustang Bio has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Mustang Bio's return on equity of -34.23% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-34.23%	-17.55%
Passage Bio	N/A	-218.59%	-72.93%

Mustang Bio is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.32	N/A

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 188.67%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

9.9% of Mustang Bio shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Passage Bio had 1 more articles in the media than Mustang Bio. MarketBeat recorded 2 mentions for Passage Bio and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.87 beat Passage Bio's score of 1.44 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Very Positive
Passage Bio	Positive

Summary

Passage Bio beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBIO vs. The Competition

Export

Metric	Mustang Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.50M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.32	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.59	16.78	12.91	6.24
Net Income	-$1.92M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-1.20%	1.74%	1.12%	1.07%
1 Month Performance	-10.40%	1.60%	1.79%	1.03%
1 Year Performance	-66.66%	56.43%	67.69%	20.77%

Mustang Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBIO Mustang Bio	1.3365 of 5 stars	$0.59 -0.1%	N/A	-68.2%	$4.50M	N/A	N/A	100	Positive News Upcoming Earnings
PLUR Pluri	1.0714 of 5 stars	$1.56 -1.0%	N/A	-65.4%	$16.83M	$1.34M	N/A	150	Analyst Upgrade Gap Up High Trading Volume
OSRH OSR	1.2612 of 5 stars	$0.46 +3.3%	N/A	-49.6%	$16.19M	$2.91M	N/A	N/A	Earnings Report Short Interest Decrease
APLT Applied Therapeutics	1.5046 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
HIND Vyome	3.2687 of 5 stars	$2.17 +0.5%	$15.00 +591.2%	N/A	$15.23M	$152.72K	N/A	50	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBIO) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mustang Bio (MBIO) Competitors